Please login to the form below

Not currently logged in
Email:
Password:

Ashfield UK makes two new business development appointments

David Tweedale and Ian Robinson add to growing team
David Tweedale Ashfield healthcare UK

Ashfield UK has appointed David Tweedale and Ian Robinson as business development managers to its commercial and clinical business.

Tweedale joins Ashfield after 11 years at Merz Pharma where more recently he served as sales and marketing manager. He also successfully launched and managed a direct competitor to Botox having joined the business at the beginning of September.

Robinson comes from Bristol-Myers Squibb where he was for 18 years in a number of roles including account manager, regional business director and sales representative. He has been involved in numerous successful launches in both cardiovascular and diabetes products.

Colin Watson, managing director of Ashfield UK, said: “We are thrilled to welcome David and Ian to the business development team. They both bring a great deal of knowledge and experience to our organisation and have joined the business at a very exciting time."

19th October 2015

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics